

Messenger Ribonucleic Acid (mRNA) and Next-Generation Vaccine Platforms Market to Reach \$82.61 Bn by 2030 at 15.8% CAGR

The Business Research Company's Messenger Ribonucleic Acid (mRNA) and Next-Generation Vaccine Platforms Global Market Size, Trends, And Forecast Report to 2035

LONDON, GREATER LONDON, UNITED KINGDOM, March 3, 2026

[/EINPresswire.com/](https://EINPresswire.com/) -- Advancements in vaccine technology have transformed

how diseases are prevented and

treated, with [messenger ribonucleic acid \(mRNA\) and next-generation vaccine platforms](#) leading this evolution. These innovative platforms are reshaping the pharmaceutical landscape by offering faster development times, greater adaptability, and more personalized approaches. Let's explore the current market outlook, key factors driving growth, regional dynamics, and notable trends in this rapidly expanding sector.



The Business Research Company's Messenger Ribonucleic Acid (mRNA) and Next-Generation Vaccine Platforms Global Market Report 2026 - Market Size, Trends, And Global Forecast 2026-2035"

The Business Research Company



The Business
Research Company

The Business Research Company Secures Position as Premier Market Research Firm in 2023, Recognized by Business Management Review.

[Significant Market Expansion in mRNA and Next-Generation Vaccine Platforms](#)

The market for messenger ribonucleic acid (mRNA) and next-generation vaccine platforms has experienced swift growth in recent years. Projections indicate the market will increase from \$39.69 billion in 2025 to \$45.88 billion in 2026, reflecting an impressive compound annual growth rate (CAGR) of 15.6%. The surge during this period is largely credited to breakthroughs in COVID-19 vaccines, foundational research on viral vectors, enhanced global pandemic preparedness, progress in genomic sequencing

technology, and initial nucleic acid vaccine trials.

Download a free sample of the messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33215&type=smp&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Feb_PR

[Forecasted Growth Outlook for mRNA and Next-Generation Vaccine Platforms](#)

Looking ahead, this market is poised for continued rapid expansion, expected to reach \$82.61 billion by 2030 at a CAGR of 15.8%. Several factors will drive this growth, including the development of personalized cancer vaccines, broadening infectious disease pipelines, faster regulatory approvals based on platform technologies, increased investment in biotech, and wider therapeutic vaccine applications. Emerging trends shaping the future include self-amplifying mRNA platforms, optimization of lipid nanoparticle delivery systems, modular vaccine designs, swift adaptation to new pathogen targets, and innovative next-generation adjuvant technologies.

Understanding mRNA and Next-Generation Vaccine Platforms

Messenger ribonucleic acid (mRNA) and next-generation vaccine platforms consist of cutting-edge vaccine methods that use genetic material—such as mRNA, DNA, or viral vectors—to instruct the body's immune system to produce protective proteins, thereby building immunity. Compared to traditional vaccines, these platforms offer faster development cycles, better scalability in manufacturing, enhanced adaptability to emerging infectious threats, and stronger immune responses.

View the full messenger ribonucleic acid (mrna) and next-generation vaccine platforms market report:

https://www.thebusinessresearchcompany.com/report/messenger-ribonucleic-acid-mrna-and-next-generation-vaccine-platforms-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Feb_PR

Personalized Medicine as a Growth Catalyst for mRNA Vaccine Platforms

A key driver propelling the mRNA and next-generation vaccine platforms market is the growing demand for personalized medicine. This medical paradigm tailors prevention and treatment strategies to an individual's unique genetic makeup, molecular traits, and health conditions. The increasing occurrence of complex and chronic diseases fuels the need for such customized therapies to improve safety and effectiveness. These vaccine platforms enable the rapid and flexible creation of highly specific vaccines and therapeutics that align with a patient's particular genetic and disease profile, supporting precision healthcare.

Rising Adoption of Personalized Treatments Boosts Market Demand

Demand for personalized medicine is gaining momentum, supported by regulatory approvals and healthcare advancements. For example, in February 2024, the Personalized Medicine Coalition—a US-based health organization—reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from six approvals in 2022. This trend highlights the expanding role of tailored therapies, further driving the adoption and growth of mRNA and next-generation vaccine platform technologies.

Regional Dynamics in the mRNA and Next-Generation Vaccine Platforms Market

In 2025, North America held the largest share of the messenger ribonucleic acid (mRNA) and next-generation vaccine platforms market. However, the Asia-Pacific region is anticipated to emerge as the fastest-growing market during the forecast period. The comprehensive market report covers important regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a global perspective on market trends and opportunities.

Browse Through More Reports Similar to the Global Messenger Ribonucleic Acid (mRNA) And Next-Generation Vaccine Platforms Market 2026, By The Business Research Company

therapeutic BCG vaccines global market report

<https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report>

vaccines global market report

<https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report>

vaccine contract manufacturing global market report

<https://www.thebusinessresearchcompany.com/report/vaccine-contract-manufacturing-global-market-report>

Speak With Our Expert:

Saumya Sahay

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email: saumyas@tbrc.info

The Business Research Company -

https://www.thebusinessresearchcompany.com/?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=home_page_test

Follow Us On:

• LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

Oliver Guirdham

The Business Research Company

+44 7882 955267

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

Facebook

X

This press release can be viewed online at: <https://www.einpresswire.com/article/897163248>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.